Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Automation Platform

By Drug Discovery Trends Editor | March 25, 2010

Freeslate, Inc. announced the launch of its third generation Core Module automation system (CM3); designed to optimize workflow integration, it enables scientists to leverage a single automated platform to run a diverse array of laboratory applications. The CM3, the latest product from Freeslate, gives scientists a configurable system for preparing, processing and testing intricate samples including biologic formulations, biomass samples, and other complex mixtures.

“We’re excited to debut our latest product offering to the chemical community at the American Chemical Society’s Spring 2010 meeting,” said John Senaldi, chief executive officer of Freeslate. “The CM3 will streamline how applications are run in today’s labs, ultimately optimizing efficiency, reducing overall R&D costs and accelerating scientific discovery for researchers.”

The CM3 unites two earlier Freeslate offerings, the Powdernium MtM and the second generation Core Module platform into a single, modular product that can be easily applied to existing lab applications. The new platform offers an extensive list of new features such as a larger deck, an automated tool changer, off-deck access with robotic arms, and a balance and imaging module that accommodates vials, bottles, jars, and plates.

The CM3 is available immediately and was showcased at the 2010 Spring ACS meeting and exposition in San Francisco, California.

Date: March 22, 2010
Source: Freeslate, Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

China’s biopharma sector enters ‘innovation 2.0’ era
The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE